Crown Bioscience Newswire

Crown Bioscience Newswire

Comprehensive Real-Time News Feed for Crown Bioscience.

Results 1 - 20 of 76 in Crown Bioscience

  1. Crownbio releases scientific posters on preclinical oncology researchRead the original story

    Monday May 14 | Malaysian National News Agency

    Crown Bioscience - a global drug discovery and development services company - has released scientific posters on innovations in CrownBio's Internal R&D focusing on preclinical oncology research. The library of poster presentations includes details on the development and application of several innovative humanized models, a new largescale ex vivo PDX drug screening service and a novel IDO1 inhibition assay platform.

    Comment?

  2. Book Theory Test Today- Theory Test BookingRead the original story w/Photo

    Apr 4, 2018 | PR-inside.com

    ... CrownBio to Showcase Scientific Expertise in Preclinical [..] SAN DIEGO, April 04, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:6554) [..] Aktia expands its special

    Comment?

  3. Suominen Corporation, notifcation of a management transaction: Kopola, NinaRead the original story w/Photo

    Mar 13, 2018 | PR-inside.com

    ... Enters Strategic Partnership with Phanes Therapeutics [..] SAN DIEGO, March 13, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:6554) [..] The much-loved New Zealand homeware brand Wallace ...

    Comment?

  4. Hemp, Inc. Signs Lucrative Consultant Agreement with HQ Global Education, Inc.Read the original story w/Photo

    Mar 13, 2018 | PR-inside.com

    ... Enters Strategic Partnership with Phanes Therapeutics [..] SAN DIEGO, March 13, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:6554) [..] Telenor Group and Ant Financial in strategic [..] ...

    Comment?

  5. Gratomic Announces Grant of Exclusive Prospecting LicenceRead the original story w/Photo

    Mar 13, 2018 | PR-inside.com

    ... Enters Strategic Partnership with Phanes Therapeutics [..] SAN DIEGO, March 13, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:6554) [..] Telenor Group and Ant Financial in strategic [..] ...

    Comment?

  6. CrownBio Enters Strategic Partnership with Phanes Therapeutics to...Read the original story w/Photo

    Mar 13, 2018 | PR-inside.com

    Crown Bioscience , a wholly-owned subsidiary of Crown Bioscience International and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announces that it has been selected by Phanes Therapeutics as a strategic partner to advance their oncology drug discovery pipeline. CrownBio provides the world's largest collection of Patient-Derived Xenograft models and is a leading provider of integrated oncology solutions that enable development of cutting-edge cancer treatments.

    Comment?

  7. REC Silicon ASA - Presentation for fixed income investor meetings commencing 12 MarchRead the original story w/Photo

    Mar 9, 2018 | PR-inside.com

    ... Ltd. ("Oasis") is the largest minority shareholder of Alpine Electronics ("Alpine" or "the Company"), [..] Crown Bioscience to Showcase Scientific Expertise at [..] SAN DIEGO, March 09, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned ...

    Comment?

  8. Crown Bioscience to Showcase Scientific Expertise at Cambridge UK...Read the original story

    Mar 9, 2018 | Customer Interaction Solutions

    Crown Bioscience , a wholly-owned subsidiary of Crown Bioscience International and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announces it will host its annual Cambridge UK symposium on Thursday, March 15th at The Cambridge Building, Babraham Research Campus. The scientific symposium, entitled "Perspectives on Oncology Drug Discovery; Immuno-Oncology and the Next Generation", will bring together some of the most influential names in preclinical oncology drug discovery.

    Comment?

  9. Upstream Works Software Announces New Partnership with CAERead the original story w/Photo

    Feb 27, 2018 | PR-inside.com

    ... , Feb. 27, [..] Webinar to Reveal Data Supporting the Use [..] SAN DIEGO, Feb. 27, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:6554) [..]

    Comment?

  10. Elemica Executives Discuss Digital Supply Chain Transformations at LogiChem 2018Read the original story w/Photo

    Feb 27, 2018 | PR-inside.com

    ... Feb. 27, [..] Webinar to Reveal Data Supporting the Use [..] SAN DIEGO, Feb. 27, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:6554) [..] Smartling and Contentful Partner to Deliver ...

    Comment?

  11. Datameer Names New Award-Winning Marketing and Sales ExecutivesRead the original story w/Photo

    Feb 27, 2018 | PR-inside.com

    ... Globenewswire Webinar to Reveal Data Supporting the Use [..] SAN DIEGO, Feb. 27, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:6554) [..] Smartling and Contentful Partner to Deliver ...

    Comment?

  12. Webinar to Reveal Data Supporting the Use of MuScreen(TM) for...Read the original story w/Photo

    Feb 27, 2018 | PR-inside.com

    Crown Bioscience , a wholly-owned subsidiary of Crown Bioscience International and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announced that Dr. Henry Li, a respected expert in preclinical pharmacology, will present a webinar showing data derived from CrownBio's large-scale immunotherapy screening platform, MuScreen . The webinar is scheduled for Thursday, March 1, 2018 at 11am EST .

    Comment?

  13. CrownBio Expands Car T-Cell Therapy PlatformRead the original story w/Photo

    Feb 20, 2018 | Contract Pharma Breaking News

    Crown Bioscience is enhancing its existing platform for chimeric antigen receptor T-cell agent evaluation with bioluminescent imaging capabilities. CAR T-cell agents utilize CAR T-cells that recognize tumor-associated antigens and subsequently promote tumor elimination.

    Comment?

  14. Car T-Cell Therapy PlatformRead the original story

    Feb 20, 2018 | Customer Interaction Solutions

    Crown Bioscience , a wholly-owned subsidiary of Crown Bioscience International and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, enhances its existing platform for chimeric antigen receptor T-cell agent evaluation with bioluminescent imaging capabilities. CAR T-cell therapies are an exciting advent in the evolving field of immune-therapeutics.

    Comment?

  15. Crown Bioscience Inc.: Car T-Cell Therapy PlatformRead the original story w/Photo

    Feb 20, 2018 | PR-inside.com

    Crown Bioscience , a wholly-owned subsidiary of Crown Bioscience International and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, enhances its existing platform for chimeric antigen receptor T-cell agent evaluation with bioluminescent imaging capabilities. CAR T-cell therapies are an exciting advent in the evolving field of immune-therapeutics.

    Comment?

  16. SpareBank 1 SMN : Corr:Key information relating to cash dividendRead the original story w/Photo

    Feb 9, 2018 | PR-inside.com

    ... Platform Revolutionizes Preclinical Development [..] SAN DIEGO, Feb. 09, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:6554) and [..] FERRARI: Ferrari N.V. to launch common shares [..] ...

    Comment?

  17. Ramirent PLC: Ramirent wins large order for rental of Temporary Space modules in NorwayRead the original story w/Photo

    Feb 9, 2018 | PR-inside.com

    ... Platform Revolutionizes Preclinical Development [..] SAN DIEGO, Feb. 09, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:6554) and [..] FERRARI: Ferrari N.V. to launch common shares [..] ...

    Comment?

  18. Enhanced MuScreena Platform Revolutionizes Preclinical Development of ImmunotherapeuticsRead the original story

    Feb 9, 2018 | Customer Interaction Solutions

    Crown Bioscience , a wholly-owned subsidiary of Crown Bioscience International and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announced new data further characterizing and enhancing the immunocompetent models included in their large-scale immunotherapy screening platform, MuScreen. Immunotherapies, alone or in combination with other drugs, treat cancer by modulating the immune system to elicit native antitumor immune responses.

    Comment?

  19. Nnit a/S: 4/2018 Notice convening Nnit Annual General MeetingRead the original story w/Photo

    Feb 9, 2018 | PR-inside.com

    ... Platform Revolutionizes Preclinical Development [..] SAN DIEGO, Feb. 09, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:6554) and [..] FERRARI: Ferrari N.V. to launch common shares [..] ...

    Comment?

  20. Enhanced MuScreen(TM) Platform Revolutionizes Preclinical Development of ImmunotherapeuticsRead the original story w/Photo

    Feb 9, 2018 | PR-inside.com

    Crown Bioscience , a wholly-owned subsidiary of Crown Bioscience International and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announced new data further characterizing and enhancing the immunocompetent models included in their large-scale immunotherapy screening platform, MuScreen. Immunotherapies, alone or in combination with other drugs, treat cancer by modulating the immune system to elicit native antitumor immune responses.

    Comment?